scholarly journals Analysis of the evidence about the efficacy and safety of the CYD-TDV dengue vaccine and its potential licensing and implementation within the Mexican Universal Vaccination Program

2016 ◽  
Vol 58 (2) ◽  
pp. 71b-83b ◽  
Author(s):  
Mauricio Hernández-Ávila ◽  
José Ignacio Santos-Preciado
Keyword(s):  
Universal Vaccination ◽  
Vaccination Program ◽  
Efficacy And Safety ◽  
Dengue Vaccine

scholarly journals Minimization of hepatitis B infection by a 25-year universal vaccination program

2012 ◽  
Vol 57 (4) ◽  
pp. 730-735 ◽  
Author(s):  
Yen-Hsuan Ni ◽  
Mei-Hwei Chang ◽  
Jia-Feng Wu ◽  
Hong-Yuan Hsu ◽  
Huey-Ling Chen ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Universal Vaccination ◽  
Vaccination Program ◽  
Hepatitis B Infection

scholarly journals Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia

2020 ◽  
Vol 39 (4) ◽  
pp. e30-e36
Author(s):  
Humberto Reynales ◽  
Gabriel Carrasquilla ◽  
Betzana Zambrano ◽  
Margarita Cortés S ◽  
Tifany Machabert ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Secondary Analysis ◽  
Trial Data ◽  
Efficacy And Safety ◽  
Dengue Vaccine

scholarly journals Dengvaxia: the world’s first vaccine for prevention of secondary dengue

2021 ◽  
Vol 9 ◽  
pp. 251513552110158
Author(s):  
Danielle Tully ◽  
Carrie L. Griffiths
Keyword(s):  
Vaccine Efficacy ◽  
Literature Search ◽  
Preventive Measures ◽  
Dengue Infection ◽  
Safety Data ◽  
Brand Name ◽  
Efficacy And Safety ◽  
Approval Process ◽  
Dengue Vaccine ◽  
To Receive

The objective of this manuscript was to review and evaluate the efficacy and safety data of Dengvaxia for the treatment of severe secondary dengue infection. Dengvaxia is the brand name for chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV). A literature search through PubMed was conducted using the keywords ‘dengue vaccine’, ‘Dengvaxia’, ‘efficacy’ or ‘safety’. Trials were selected if they appropriately assessed vaccine efficacy or were related to the vaccine approval process for CYD-TDV. Findings from this review underline the evolution of vaccine efficacy against seroprevalence, serotypes, and various ages. There are currently no preventive measures or antiviral treatments for dengue; CYD-TDV is the first vaccine to receive US Food and Drug Administration approval. Protective responses seen with the complete administration of CYD-TDV can become a standardized tool as part of a world vaccination program.

Sign in / Sign up

Export Citation Format

Share Document